Eli Lilly and Company

Dana Rae Benesh

Maria-Jesus Blanco-Pillado

Yao-Chang Xu

Sandra Ann Filla

Daniel Timothy Kohlman

Bai-Ping Ying

Brian Michael Mathes

Deyi Zhang

Kevin John Hudziak

Thomas Daniel Aicher

Tony P Tang

Charles Howard Mitch

Kumiko Takeuchi

Frantz Victor

Fredrik Pehr Marmsater

Jeffrey Michael Schkeryantz

Guillermo S Cortez

Michael Philip Cohen

James Allen Knobelsdorf

Albert Khilevich

Todd Michael Groendyke

DeAnna Piatt Zacherl

Maria Jesus Blanco-Pillado

Fredrik Pehr Marmsäter

The present invention provides compounds of formula (I); pharmaceutical compositions thereof, and methods of using the same, processes or preparing the same, and intermediates thereof. 

Potentiators of glutamate receptors

The present invention relates to compounds of formula I: or a pharmaceutically acceptable acid addition salt thereof, wherein X is C(R3)&#x2550; or N&#x2550;; Ris C-Calkyl, substituted C-Calkyl, C-Ccycloalkyl, substituted C-Ccycloalkyl, phenyl, substituted phenyl, heterocycle, or substituted heterocycle; Ris hydrogen, C-Cn-alkyl, C-Ccycloalkyl-C-Calkyl, or a group of formula II provided that when Ris C-Calkyl or substituted C-Calkyl, Ris hydrogen or methyl; R, Rand, when X is &#x2014;C(R)&#x2550;, R, are each independently hydrogen, fluoro, or methyl, provided that no more than one of R, R, and Rmay be other than hydrogen; Ris hydrogen or C-Calkyl; Ris hydrogen, C-Calkyl, or C-Ccycloalkylcarbonyl, provided that when Ris other than hydrogen, Ris hydrogen; Ris hydrogen or C-Calkyl; and n is an integer from 1 to 6 inclusively. The compounds of the present invention are useful for activating 5HTreceptors, inhibiting neuronal protein extravasation, and for the treatment or prevention of migraine in a mammal.

Substituted 2-carbonylamino-6-piperidinaminopyridines and substituted 1-carbonylamino-3-piperidinaminobenzenes as 5-HT1F agonists

The present invention relates to compounds of formula 1: and pharmaceutically acceptable acid addition sails thereof. The compounds of the present invention are useful for activating 5-HTreceptors, inhibiting neuronal protein extravasation, and for the treatment or preverition of migraine in mammals, particularly humans. 

[object Object]

A compound of the formula I: (I) wherein the variables are as described herein, or a pharmaceutically acceptable salt, solvate, enantiomer, racemate, diastereomer or mixture thereof, formulations and methods of use thereof are disclosed. 

Opioid receptor antagonists

The present invention relates to compounds of formula I: (I) or a pharmaceutically acceptable acid addition salt thereof, where; X is C(R&#x2550; or N&#x2550;; Ris C&#x2013;Calkyl, substituted C&#x2013;Calkyl, C&#x2013;Ccycloalkyl, substituted C&#x2013;Ccycloalkyl, phenyl, substituted phenyl, heterocycle, or substituted heterocycle; Ris hydrogen, C&#x2013;Cn-alkyl, C&#x2013;Ccycloalkyl-C&#x2013;Calkyl, or a group of formula II (II) provided that when Ris C&#x2013;Calkyl or substituted C&#x2013;Calkyl, Ris hydrogen or methyl; R, R, and, when X is C(R)&#x2550;, R, are each independently hydrogen, fluoro, or methyl, provided that no more than one of R, R, and Rmay be other than hydrogen; Ris hydrogen or C&#x2013;Calkyl; Ris hydrogen, C&#x2013;Calkyl, or C&#x2013;Ccycloalkylcarbonyl, provided that when Ris other than hydrogen, Ris hydrogen; Ris hydrogen or C&#x2013;Calkyl; and n is an integer from 1 to 6 inclusively. The compounds of the present invention are useful for activating 5-HTreceptors, inhibiting neuronal protein extravasation, and for the treatment or prevention of migraine in a mammal. 

A compound of the formula (I) wherein the variables Xto X, Rto Rincluding R, E, q, v, y, z, A and B are as described, or a pharmaceutically acceptable salt, solvate, enantiomer, racemate, diastereomer or mixtures thereof, useful for the treatment, prevention or amelioration of obesity and Related Diseases is disclosed 

Growing community of inventors

Westfield, IN, United States of America

Dana Rae Benesh